Search Results 231-240 of 20696 for colitis

  1. Publications - Konstantinos A. Papadakis, M.D. - Mayo Clinic

    Crohns Colitis 360. 2021 Jul; 3 (3):otab019 Epub 2021 May 17 ... Apolipoprotein A-I inhibits experimental colitis and colitis-propelled carcinogenesis.

  2. Crohn's disease - Doctors and departments - Mayo Clinic

    ... colitis, Microscopic colitis, Immune-...related adverse event. Show more areas of focus for Gui Piovezani Ramos, M.D.. D. Dean ...

  3. Crohn's disease - Doctors and departments - Mayo Clinic

    ... colitis, Hemorrhoids, Anal cancer, Colon polyps, Rectal cancer ... colitis, Microscopic colitis, Immune-...related adverse event. Show more ...

  4. Identifying diarrhea caused by bile acid malabsorption - Mayo Clinic

    ... colitis. Even so, BAM is seldom considered in most cases of chronic diarrhea encountered by gastroenterologists and primary care physicians. As a result ...

  5. Inflammatory bowel disease biobank research update - Mayo Clinic

    The goal of the biobank is to collect biospecimens (serum, tissue, stool and urine) from patients diagnosed with ulcerative colitis (UC) or Crohn's disease ...

  6. Crohn's disease - Doctors and departments - Mayo Clinic

    ... colitis, Inflammatory bowel ... Colonoscopy, Flexible sigmoidoscopy, Upper endoscopy, Ulcerative colitis, Crohn's disease, Microscopic colitis, Immune-...

  7. Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease - Mayo Clinic

    ... colitis, radiation colitis, diverticular disease associated with colitis, or microscopic colitis. Active infections; Chronic hepatitis B virus (HBV) or C ...

  8. Vedolizumab (intravenous route, subcutaneous route) - Side effects & dosage - Mayo Clinic

    Vedolizumab injection is used to treat moderate to severe active Crohn's disease and ulcerative colitis. This medicine is a monoclonal antibody that works ...

  9. Examining clinical and genetic factors that impact response to anti-TNF agents in patients with IBD

    Approved in 1998 for use in treating Crohn's disease and subsequently in 2005 for treating ulcerative colitis, anti-tumor necrosis factor (TNF) agents have ...

  10. A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis (ANTHEM-UC) - Mayo Clinic

    A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis (ANTHEM-UC). Print details. Share; Facebook · Twitter.